Revenue
2021
2022
2023
2024
2025
Bioregenx, Inc. (BRGX)
Price$0.0055Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.9M | $2.3M | $3.4M | $42,159 | $198,584 |
| Gross profit | $1.5M | $1.7M | $2.3M | $42,159 | $198,030 |
| Gross margin | 81.08% | 70.87% | 67.76% | 100.00% | 99.72% |
| Research & development | $31,750 | $0 | $257,723 | — | — |
| Operating expenses | $2.7M | $24.4M | $5.7M | $120,467 | $363,148 |
| Operating income | −$1.2M | −$22.8M | −$3.4M | −$78,308 | −$165,118 |
| Operating margin | −67.08% | −972.75% | −99.92% | −185.74% | −83.15% |
| EBITDA | −$1.2M | −$20.5M | −$3.4M | −$72,376 | — |
| EBITDA margin | −63.03% | −877.92% | −99.78% | −171.67% | — |
| Net income | −$1.5M | −$23.1M | −$3.6M | −$78,308 | −$96,873 |
| Net profit margin | −83.23% | −985.17% | −105.53% | −185.74% | −48.78% |
| Basic EPSper basic share | $0.00 | -$0.03 | -$0.01 | $0.00 | $0.00 |
| Diluted EPSper diluted share | $0.00 | -$0.03 | -$0.01 | $0.00 | $0.00 |
Owners
Reported shareholders